First mRNA Flu Shot, Alzheimer's Goes Home, and August's Drug Slate
First mRNA flu vaccine approved; Alzheimer's dosing goes home; a new myeloma drug class, a rare bone disease cure, and an AI drug hit pivotal trial.
By BINA Editorial
August is shaping up as one of the busiest regulatory months of 2026: a landmark vaccine cleared yesterday, a treatment that moves Alzheimer's care from clinic to kitchen table is days from market, and four more FDA decisions are queued for the weeks ahead.
The First mRNA Flu Vaccine Is Approved
On August 5, the FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults 50 and older — making it the first mRNA flu product licensed in the United States and Moderna's fourth approved product overall.
The road to approval was not straight. The FDA initially refused to file the application, arguing the control arm in Moderna's Phase III trial did not reflect the best available standard of care in the US at the time. After a Type A meeting with regulators, the FDA agreed to proceed with review. A 9-0 advisory committee vote in favour of mFLUSIVA across both the 50–64 and 65+ age bands then cleared the path to a standard approval.
The clinical data show mFLUSIVA produced a relative vaccine efficacy of 26.6% compared to standard-dose comparator vaccines in the overall population, rising to 27.4% in adults 65 and older. Reactogenicity — injection-site pain and transient systemic symptoms — was more frequent with mFLUSIVA than with comparators, though events were predominantly mild-to-moderate and resolved within one to two days. A postmarketing study will be required to verify long-term clinical benefit. Moderna expects the vaccine to be available for the 2026–2027 respiratory virus season.
The significance of this approval goes beyond Moderna's commercial pipeline. mRNA flu vaccines have been in clinical development for years, dogged by comparator selection debates and regulatory hurdles. mFLUSIVA's clearance validates the mRNA platform for a routine seasonal indication — moving the technology from pandemic emergency into annual preventive care.
Alzheimer's Treatment Is Moving Out of the Clinic
Biogen and Eisai's LEQEMBI IQLIK (lecanemab-irmb), a subcutaneous formulation of the approved anti-amyloid drug lecanemab, received FDA approval on July 13 for use as an initiation dose in early Alzheimer's disease. It is expected to be commercially available in late August — meaning it arrives on pharmacy shelves this month.
The clinical significance is real. The original intravenous lecanemab requires biweekly infusions at an infusion centre, each taking around an hour. The subcutaneous version is administered at home once weekly, with each injection taking approximately 15 seconds. The approved initiation regimen is 500 mg weekly delivered as two 250 mg injections; after 18 months of IV or subcutaneous treatment, patients can transition to a 360 mg weekly maintenance dose.
LEQEMBI IQLIK is the world's first anti-amyloid Alzheimer's therapy approved for at-home initiation dosing. The practical consequence is access: patients in areas with limited infusion centre capacity, older adults who struggle with frequent clinic visits, and people in rural or underserved regions can now begin and continue disease-modifying Alzheimer's treatment without leaving home. The drug does not reverse Alzheimer's disease — it slows progression in early stages — but removing the logistical friction of clinic-based infusions substantially widens the pool of patients who can realistically sustain the regimen.
A New Drug Class for Multiple Myeloma Has an August 17 Deadline
Bristol Myers Squibb's iberdomide, combined with daratumumab and dexamethasone, has an FDA target action date of August 17 for the treatment of relapsed or refractory multiple myeloma. Iberdomide is the first potential approval from a class called cereblon E3 ligase modulators (CELMoDs) — a mechanistic successor to immunomodulatory drugs like lenalidomide and pomalidomide that have anchored myeloma treatment for two decades.
The application carries both Breakthrough Therapy Designation and Priority Review, based on data from the Phase 3 EXCALIBER-RRMM trial. That study showed iberdomide plus daratumumab and dexamethasone significantly improved minimal residual disease (MRD) negativity rates compared to standard of care in patients whose myeloma had relapsed or become refractory to prior therapy.
MRD negativity — the absence of detectable cancer cells at the most sensitive available assay level — has emerged as an important surrogate endpoint in myeloma because deep responses correlate with longer progression-free and overall survival. If the FDA approves iberdomide on schedule, patients with myeloma that has stopped responding to existing regimens gain access to the first member of an entirely new drug class — one that works through a distinct molecular mechanism that existing drugs have not depleted.
The First Treatment for a Rare Bone Disease Could Arrive This Month
Regenerons garetosmab, an anti-Activin A monoclonal antibody, is under FDA Priority Review with an August 2026 PDUFA target date for fibrodysplasia ossificans progressiva (FOP) — an ultra-rare genetic disorder affecting roughly 900 people worldwide that causes progressive ectopic bone formation in soft tissues, gradually locking muscles, tendons, and joints in place.
There is currently no approved treatment for FOP. Garetosmab's Biologics License Application is supported by the Phase 3 OPTIMA trial, which showed the drug reduced the number and volume of new heterotopic bone lesions by 94% in adults with FOP-causing type I Activin receptor variants. Activin A is the protein garetosmab neutralises — it is a central driver of the abnormal bone-formation cascade that defines FOP.
For 900 people worldwide living with a disease that progressively calcifies soft tissue into bone, an FDA approval is not an incremental gain — it is the only treatment. The scale of unmet need is total, and the Phase 3 efficacy signal is among the strongest seen in a rare bone disease trial.
An AI-Designed Drug Enters Its Pivotal Trial
Insilico Medicine has initiated a Phase III clinical trial for rentosertib (ISM001-055), a potentially first-in-class oral small-molecule inhibitor of TNIK (Traf2- and NCK-interacting kinase) for idiopathic pulmonary fibrosis (IPF). Rentosertib is one of the most advanced drugs whose target identification, molecular design, and clinical candidate selection were all performed by an AI platform — making its Phase III entry a milestone for the field of AI-driven drug discovery.
The Phase IIa GENESIS-IPF study provided the clinical evidence to advance: the 60 mg once-daily arm showed a mean forced vital capacity improvement of +98.4 mL at 12 weeks, a meaningful signal in a disease defined by relentless lung function decline. The Phase III trial will enrol 320 patients across 47 centres in China in a randomised, double-blind, placebo-controlled design.
IPF has a median survival of two to five years from diagnosis and no curative treatment. The two currently approved drugs — nintedanib and pirfenidone — slow progression but do not reverse it. Rentosertib, as a first-in-class TNIK inhibitor, represents a mechanistically distinct approach to a disease that still kills the majority of patients within five years of diagnosis. Its Phase III launch is the clearest evidence yet that AI drug discovery is not just accelerating target validation and candidate selection — it is producing drugs that reach the pivotal testing that precedes regulatory approval.
Lower Vitamin D Predicts Combined Depression and Cognitive Decline in the Oldest Diabetics
A study of adults over 85 with diabetes found that lower vitamin D levels were independently associated with having both depressive symptoms and mild cognitive impairment at the same time. Each 1 ng/mL increase in measured vitamin D concentration was associated with a 23% lower likelihood of presenting with both conditions concurrently — an association that held after controlling for other variables.
The finding matters because it targets co-occurrence, not just individual risk. Depression and mild cognitive impairment each occur independently in older adults with diabetes with high frequency, but their simultaneous presence is a stronger predictor of progression to full dementia and poorer functional outcomes than either condition alone. The vitamin D signal, if it reflects a causal pathway, would suggest a potentially modifiable risk factor for the combined syndrome.
No interventional trial has yet tested whether correcting vitamin D deficiency in this specific population reduces joint incidence of depression and cognitive impairment. But the observational evidence is strong enough to strengthen the case for routine vitamin D monitoring in diabetic patients over 85 — a group where interventions that delay cognitive decline carry especially high value given the age-related ceiling on other preventive options.
Six stories, all landing in the same fortnight, pointing at the same structural shift: the distance between a scientific result and a patient-facing intervention is getting shorter. An mRNA vaccine spent years in regulatory limbo and cleared yesterday. An Alzheimer's therapy steps out of the infusion suite and into the home this month. An AI-designed compound crosses into pivotal testing. The pipeline is moving faster than it ever has. Whether the outcomes justify the pace is a question that post-market data will answer — one cohort at a time.